Bevacizumab, a VEGF inhibitor approved for oncological use in metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, and cervical cancer, has been associated to optic neuropathy. This evidence concerns the gene VEGFA and metastatic colorectal cancer.